Skip to content
Pep My LifePeptides, decoded for real life.

BPC-157 · Research breakdown

What the BPC-157 research actually says

Every study, translated. This is the depth behind the BPC-157 overview — read it if you want the receipts.

Last reviewed September 3, 202612 sources
Back to the plain-English BPC-157 overview

How strong is the evidence, dimension by dimension?

Human research exists — it just doesn't say what the internet says it says.

Overall evidence

Early / very limited human evidence

Lots of animal research, a little human research, no established clinical healing indication.

Musculoskeletal animal research

Substantial preclinical

Repeated tendon, ligament, muscle and myotendinous injury models.

GI animal research

Substantial preclinical

A long history across stomach, intestinal, colitis and ischemia/reperfusion models.

Long-term human safety

Insufficient

Short studies, small samples, unclear monitoring. No basis for a long-term profile.

Evidence by route

These are graded separately on purpose. Evidence from one route of administration does not carry over to another.

Human musculoskeletal evidence

Very limited

One uncontrolled retrospective chart review, with self-reported outcomes and no imaging.

Human GI evidence

Limited / incomplete

A randomised placebo-controlled UC study — reported only as a meeting abstract.

Subcutaneous human evidence

Insufficient

The route people actually discuss. FDA reported no human pharmacokinetic data for it.

These are graded separately because BPC-157's human studies used completely different routes for completely different conditions. Collapsing them into one number would let a bladder study and a knee chart review vouch for subcutaneous injection, which is exactly the error this page exists to prevent.

How we grade evidence

Here's the reality check.

FDA's 2026 review identified five clinical studies or reports in which humans actually received BPC-157. That is very different from “no human research”. It is also very different from a mature clinical evidence base.

clinical studies identified by FDA in its 2026 review
5clinical studies identified by FDA in its 2026 review

Sources1

Identity: free base vs acetate

Before any evidence question, there is a characterisation question. FDA treats BPC-157 free base and BPC-157 acetate as distinct bulk drug substances, and identifiers published for one do not describe the other.

Why this matters for reading the literature

FDA raised naming and characterisation concerns because products sold under the common name “BPC-157” may represent different forms. Two sources describing “BPC-157” are not guaranteed to be describing the same substance, and the free-base CAS, UNII, formula and mass should not be assigned automatically to any vial carrying the generic name.

Sources1

Tendon and ligament research

Preclinical

The origin of the healing reputation, and the clearest example of how strong an animal result can look.

Animal

Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat

Cerovecki T, et al. · J Orthop Res 2010 28(9):1155–1161

PMID 20225319DOI 10.1002/jor.21107

Study type
Surgically transected medial collateral ligament model in rats

What researchers did

Surgically transected the medial collateral ligament in rats, then assessed healing across functional, biomechanical, macroscopic and histologic measures.

What they found

Improvements were reported across all four categories of measurement compared with controls.

What that actually tells us

This is a strong, multi-measure preclinical result — not a single soft endpoint, which is part of why the finding carried so much weight.

What it doesn't tell us

It is a surgically injured rat ligament. It does not establish that BPC-157 repairs ACLs, rotator cuffs, tendon tears or sports injuries in humans.

Sources8

Muscle and myotendinous research

Preclinical

Severe experimental injury models in rats, including disrupted myotendinous junctions and muscle-to-bone reattachment.

Animal

Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

Japjec M, Horvat Pavlov K, Petrovic A, et al. · Biomedicines 2021 9(11):1547

PMID 34829776DOI 10.3390/biomedicines9111547PMCID PMC8615275

Study type
Rat model of disrupted myotendinous junction

What researchers did

Assessed BPC-157 in rat models involving disruption of the junction between muscle and tendon.

What they found

Investigators reported improvements across functional, structural and biomechanical assessments.

What that actually tells us

The repair signal is not limited to ligament — it reproduces at the muscle-tendon interface in the same species.

What it doesn't tell us

Nothing about athletes, human muscle tears, or recovery timelines in people.

Animal

Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats

Matek D, Matek I, Staresinic E, et al. · Pharmaceutics 2025 17(1):119

PMID 39861766DOI 10.3390/pharmaceutics17010119PMCID PMC11768438

Study type
Rat muscle-to-bone reattachment model

What researchers did

Examined BPC-157 in a newer rat model of muscle reattachment to bone.

What they found

Reported effects on repair in that model.

What that actually tells us

The preclinical programme is still active rather than historical.

What it doesn't tell us

Again, rat surgery. It does not transfer to human tendon-to-bone repair or post-operative recovery.

Sources910

Gastrointestinal research

Preclinical

The oldest thread. Animal work spans stomach and intestinal injury, colitis, ischemia/reperfusion, NSAID-related damage and fistula models.

Animal

Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights

Duzel A, Vlainic J, Antunovic M, et al. · World J Gastroenterol 2017 23(48):8465–8488

PMID 29358856DOI 10.3748/wjg.v23.i48.8465PMCID PMC5752708

Study type
Rat colitis and ischemia/reperfusion models

What researchers did

Investigated BPC-157 in rat models of colitis and ischemia/reperfusion injury.

What they found

Reported protective and repair-associated effects in those models.

What that actually tells us

The GI research thread is substantive and long-running, and it predates the musculoskeletal reputation.

What it doesn't tell us

It does not establish treatment of any human gastrointestinal condition, and it does not support “gut healing” as a general claim.

We deliberately cite a small number of primary animal papers here rather than stacking reviews, which would inflate the apparent number of independent experiments.

Sources11

Every human study, one at a time

Preclinical / Early Human

FDA's 2026 review summarised human exposure from five studies. They are listed here individually because summarising them together is how they get overstated.

HumanRectalConference abstract

Placebo-controlled phase-1 tolerability and pharmacokinetic work in healthy volunteers

Veljaca M, et al. · 2003

Reported only as meeting abstracts, which carry less evidentiary weight than a full peer-reviewed report.

Study type
Placebo-controlled phase-1 tolerability/PK study, reported in meeting abstracts. 32 randomised, 24 reportedly exposed
Population / model
Healthy volunteers
Route
Rectal
Sample size
32 randomised / 24 exposed

What researchers did

Ran early placebo-controlled tolerability and pharmacokinetic work using a rectal route in healthy volunteers.

What they found

The most frequently reported adverse events were headache and flatulence, without an obvious difference versus placebo according to the abstract.

What that actually tells us

People have received BPC-157 in a controlled setting, and nothing alarming was reported in that small group.

What it doesn't tell us

It is abstract-only, so methods and full results are not available for scrutiny. It says nothing about subcutaneous use or about efficacy for anything.

HumanRectalConference abstract

Multicentre randomised, double-blind, placebo-controlled study in mild-to-moderate ulcerative colitis

Ruenzi M, et al. · 2005

Reported only as a meeting abstract, not a complete peer-reviewed trial report.

Study type
Randomised, double-blind, placebo-controlled two-week rectal-enema trial, reported in a meeting abstract
Population / model
People with mild-to-moderate ulcerative colitis
Route
Rectal
Sample size
53 randomised / 46 completed

What researchers did

Randomised 53 people roughly 1:1 to BPC-157 rectal enema or placebo for two weeks; 46 completed.

What they found

Results were reported in a 2005 meeting abstract. FDA noted major missing information rather than a clear efficacy result.

What that actually tells us

A genuine randomised, placebo-controlled human trial of BPC-157 was conducted. That is more than most peptides in this space can say.

What it doesn't tell us

FDA found the primary endpoint insufficiently defined, inclusion and exclusion criteria unclear, statistical methods unclear and follow-up limited, and concluded the information was inadequate to establish efficacy and safety for ulcerative colitis. It does not extend to Crohn's disease, celiac disease or tendonitis, for which FDA identified no clinical studies.

HumanIntra-articular

Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

Lee E, Padgett B. · Altern Ther Health Med 2021 27(4):8–13

PMID 34324435

Study type
Retrospective chart review, no control group
Population / model
People treated for knee pain; diagnoses varied
Route
Intra-articular
Sample size
17 identified / 16 contacted / 12 received BPC-157 alone

What researchers did

Reviewed charts of patients who had received intra-articular BPC-157 injections for knee pain, some with BPC-157 alone and some in combination.

What they found

The authors reported improvement in many patients.

What that actually tells us

This is legitimate human exposure and effect data, and it is the most-cited human musculoskeletal source for BPC-157.

What it doesn't tell us

It was retrospective with no placebo or control group, diagnoses and follow-up varied, outcomes relied heavily on patient report, there was no standardised functional assessment and no MRI confirmation of tissue repair. It is not proof that cartilage was regenerated or that torn tissue was structurally repaired.

HumanIntravesical

Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study

Lee E, Walker C, Ayadi B. · Altern Ther Health Med 2024 30(10):12–17

PMID 39325560

Study type
Single-arm pilot study, one intravesical procedure
Population / model
12 women with interstitial cystitis
Route
Intravesical
Sample size
12

What researchers did

Administered a single intravesical procedure to twelve women with interstitial cystitis and tracked symptoms.

What they found

Reported symptom improvement and no adverse events.

What that actually tells us

Another small human exposure, in a specific condition and by a specific route.

What it doesn't tell us

Single-arm with twelve participants, so no comparison group. It is route- and condition-specific and cannot be generalised to subcutaneous BPC-157 or to musculoskeletal repair.

HumanIntravenous

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee E, Burgess K. · Altern Ther Health Med 2025 31(5):20–24

PMID 40131143

Study type
IRB-approved pilot, short-term tolerability
Population / model
2 healthy adults
Route
Intravenous
Sample size
2

What researchers did

Gave intravenous infusions to two healthy adults and monitored short-term tolerability.

What they found

No adverse effects were reported in the limited monitored period.

What that actually tells us

Essentially, that the procedure was performed and observed.

What it doesn't tell us

Two people cannot characterise population-level safety for any route, and an IV infusion says nothing about chronic subcutaneous use.

Sources134567

Why the routes cannot be pooled

The five human studies used four different routes. The route almost nobody studied is the one almost everybody discusses.

What each route does and does not license

Intra-articular knee injection does not establish what happens after a subcutaneous abdominal injection. An intravesical bladder procedure does not establish systemic tissue-repair effects. Two intravenous participants do not establish chronic subcutaneous safety. And FDA reported no human pharmacokinetic data after subcutaneous administration at all.

Sources1

What about mechanism?

Mechanistic

Plenty has been proposed. Little has been established.

Reported pathway involvement

The literature describes reported changes involving nitric oxide signalling, angiogenesis, growth-factor-related signalling, fibroblast behaviour and inflammatory signalling. Note the wording: reported changes, in experimental systems.

No established molecular target

FDA's 2026 review stated that BPC-157's molecular targets are not established and that its mechanisms remain poorly understood. Several mechanisms have been proposed, but no single established target explains the reported effects.

Why we phrase it carefully

“BPC-157 works by activating X” is a claim the literature does not currently support. “Researchers have reported changes involving X” is what the evidence actually says, and the difference is not pedantry — it is the difference between a hypothesis and a mechanism of clinical benefit.

Sources1

Safety and pharmacokinetic limitations

What FDA found, stated without rounding it up or down.

FDA's 2026 findings on safety

  • No serious adverse events apparently reported in the small clinical studies reviewed
  • Safety monitoring unclear in most studies
  • Studies short, samples small, doses and routes exploratory
  • Three FAERS reports involving injectable products, with limited causal interpretation
  • No formal studies identified assessing immunogenicity
  • Peptide aggregation and impurities among FDA's concerns
  • Clotting- and liver-associated signals in nonclinical repeat-dose rat and dog studies, relevance to humans unknown
  • No human pharmacokinetic data after subcutaneous administration

FDA explicitly said FAERS alone cannot establish causality or characterise BPC-157's safety. Adverse-event reports are signals, not established side effects — and animal safety findings do not establish human safety in either direction.

Sources1

The translation problem

A 2025 systematic review is the clearest statement of both halves: a large preclinical literature, and very little human evidence.

ReviewSystematic review

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

Vasireddi N, et al. · HSS J 2025 21(4):485–495

PMID 40756949

Study type
Systematic review of BPC-157 in orthopaedic sports medicine

What researchers did

Systematically reviewed the BPC-157 literature relevant to orthopaedic sports medicine.

What they found

A large body of preclinical work involving muscle, tendon, ligament and bone injuries, with improvements reported in functional, structural and biomechanical outcomes — alongside a scarcity of meaningful human evidence.

What that actually tells us

Both halves of the BPC-157 story at once, from a single source: the preclinical volume is real, and so is the human gap.

What it doesn't tell us

A systematic review inherits the limits of what it reviews. It cannot supply human evidence that was never generated.

Sources12

FDA's 2026 evaluation and the PCAC vote

FDA reviewed BPC-157 free base and BPC-157 acetate for possible inclusion on the Section 503A Bulks List, focusing its scientific evaluation on ulcerative colitis. FDA staff concluded that the evaluation criteria weighed against placing either substance on the list. The advisory committee then voted 8 in favour, 6 against, with 1 abstention, in favour of recommending inclusion.

Two things are true at once

FDA staff raised serious evidence and quality concerns, and the committee still narrowly recommended inclusion. Neither cancels the other. The recommendation is advisory and non-binding; it is not FDA approval, it does not establish safety or efficacy, and it does not resolve the staff review's concerns.

Sources21

What we know, and what we don't

What we know

  • BPC-157 is a synthetic 15-amino-acid peptide, also developed under the name PL-14736.
  • There is a large experimental literature reporting repair-associated effects in animal injury models.
  • Tendon, ligament, muscle and gastrointestinal models are the best-developed preclinical areas.
  • Human research exists: FDA identified five clinical studies or reports involving human administration.
  • Those human studies used four different routes across four different conditions.

What we don’t know

  • Whether BPC-157 heals tendons, ligaments, muscle or cartilage in humans.
  • What happens pharmacokinetically after subcutaneous administration in people.
  • Whether any of the animal repair findings translate to real-world human injury.
  • Long-term human safety, immunogenicity, or the effect of product impurities.
  • Whether products sold as “BPC-157” are consistently the same substance.
  • A validated human regimen for any indication.

References

  3. HumanRectalConference abstract

    Placebo-controlled phase-1 tolerability and pharmacokinetic work in healthy volunteers

    Veljaca M, et al. · 2003

    Meeting abstracts only — no full peer-reviewed report identified.

    32 randomised, 24 reportedly exposed. Reported only as meeting abstracts; headache and flatulence most frequently reported, without an obvious difference versus placebo.

  4. HumanRectalConference abstract

    Multicentre randomised, double-blind, placebo-controlled study in mild-to-moderate ulcerative colitis

    Ruenzi M, et al. · 2005

    Meeting abstract only — methods and full results unavailable for scrutiny.

    53 randomised, 46 completed, two-week rectal enema. Reported only as a meeting abstract; FDA judged the information inadequate to establish efficacy and safety for ulcerative colitis.

  5. HumanIntra-articular

    Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain

    Lee E, Padgett B. · Altern Ther Health Med 2021 27(4):8–13

    PMID 34324435

    Retrospective chart review, no control group. Reported improvement in many patients; no standardised functional assessment and no imaging confirmation of tissue repair.

  6. HumanIntravesical

    Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study

    Lee E, Walker C, Ayadi B. · Altern Ther Health Med 2024 30(10):12–17

    PMID 39325560

    Single-arm pilot in 12 women, one intravesical procedure. Reported symptom improvement and no adverse events.

  7. HumanIntravenous

    Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

    Lee E, Burgess K. · Altern Ther Health Med 2025 31(5):20–24

    PMID 40131143

    IRB-approved pilot in 2 healthy adults. No adverse effects reported in the limited monitored period.

  8. Animal

    Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat

    Cerovecki T, et al. · J Orthop Res 2010 28(9):1155–1161

    PMID 20225319DOI 10.1002/jor.21107

    Surgically transected rat medial collateral ligament model. Improvements reported across functional, biomechanical, macroscopic and histologic measures.

  9. Animal

    Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats

    Japjec M, Horvat Pavlov K, Petrovic A, et al. · Biomedicines 2021 9(11):1547

    PMID 34829776DOI 10.3390/biomedicines9111547PMCID PMC8615275

    Rat myotendinous junction disruption model; improvements reported across functional, structural and biomechanical assessments.

  10. Animal

    Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats

    Matek D, Matek I, Staresinic E, et al. · Pharmaceutics 2025 17(1):119

    PMID 39861766DOI 10.3390/pharmaceutics17010119PMCID PMC11768438

    Rat muscle-to-bone reattachment model after surgical detachment of the quadriceps.

  11. Animal

    Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights

    Duzel A, Vlainic J, Antunovic M, et al. · World J Gastroenterol 2017 23(48):8465–8488

    PMID 29358856DOI 10.3748/wjg.v23.i48.8465PMCID PMC5752708

    Representative primary animal paper for the gastrointestinal research thread.

  12. ReviewSystematic review

    Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review

    Vasireddi N, et al. · HSS J 2025 21(4):485–495

    PMID 40756949

    Large preclinical body across muscle, tendon, ligament and bone injuries, alongside a scarcity of meaningful human evidence.

Looking for the short version instead?

Read the BPC-157 overview →

Stay current

New research, decoded and sent to you

Occasional emails when we publish something worth your time. No hype, no product pitches.

Signup opens soon.